Its lead investigational gene therapy, GT005, is currently being evaluated in Phase II clinical trials for the treatment of geographic atrophy (GA) ...
https://www.google.com/url?rct=j&sa=t&url=https://www.biopharma-reporter.com/Article/2021/11/09/Sanofi-invests-up-to-60m-in-Gyroscope-Therapeutics&ct=ga&cd=CAIyGmEyNDJjNTAxZWU3OTQyNzI6Y29tOmVuOlVT&usg=AFQjCNFuFLDSP9QGF5GHhWs06uvxPLVhbQ
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.